On Monday, Oncothyreon Inc (USA) (NASDAQ:ONTY)’s shares declined -0.24% to $4.08.
Shares of Oncothyreon Inc (ONTY) stated positive study data for its breast cancer treatment.
The drug candidate, called ONT-380, met tolerability standards in early-stage development and will move ahead to midstage development, where more focus will be placed on its potential effectiveness.
The results so far are from the drug candidate’s Phase I development, which is the earliest stage of clinical development and typically only focuses on safety and side effects. They involve too few patients to determine whether a drug is actually effective, though, the company said the results are encouraging.
The company is pairing ONT-380 with Xeloda and Herceptin as a third-line treatment for metastatic breast cancer patients who also have the HER2 protein. The protein promotes the growth of cancer cells.
Another early study focused on breast cancer that has spread to the central nervous system.
Both Xeloda and Herceptin are made by Genentech, which is part of Roche Holding AG.
Oncothyreon Inc., a clinical-stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of cancer. Its clinical-stage product candidates comprise ONT-380, an orally active and selective small-molecule HER2 inhibitor, which is in two Phase 1b trials, one in combination with Kadcyla and another in combination with Xeloda and/or Herceptin; and ONT-10, a therapeutic vaccine in Phase 1 trial targeting the Mucin 1 peptide antigen (MUC1) for use in various cancer indications, counting breast, thyroid, colon, stomach, pancreas, ovarian, and prostate, in addition to certain types of lung cancer.
Golar LNG Limited (USA) (NASDAQ:GLNG)’s shares dropped -4.10% to $46.51.
Golar LNG Ltd. (GLNG) will be trading ex-dividend of a total dividend of $0.45 per share on June 10, 2015. The record date will be June 12, 2015 and the dividend will be paid on or about June 26, 2015.
Golar LNG Limited, a midstream liquefied natural gas (LNG) company, engages in the transportation, regasification, liquefaction, and trading of LNG. The company operates in three segments: Vessel Operations, LNG Trading, and FLNG. It is involved in the acquisition, ownership, operation, and chartering of LNG carriers and floating storage regasification units (FSRUs); and the development of LNG projects.
At the end of Monday’s trade, XL Group plc (NYSE:XL)‘s shares dipped -0.65% to $36.80.
XL Group plc (XL) delivered operating earnings per share in the first quarter that were in line with the Zacks Consensus Estimate but declined year over year due to lower levels of associate and life reinsurance income.
XL Group has always eyed planned acquisitions to ramp up its operational results. To that end, the company attained Catlin Group for more alternative capital opportunities and business in the Lloyd’s platform.
Moreover, XL Group remains optimistic about XL Innovate, the XL sponsored venture capital fund as it will invest in companies that have a planned focus on developing new capabilities in the insurance sector. With strong international exposure and diverse product offerings, we believe that the company is well positioned to write higher premiums to drive top-line growth.
A strong capital and liquidity position enables XL Group Limited to enhance its shareholders’ value. There were no repurchases made in the first quarter as the company suspended the same due to the Catlin acquisition. However, XL Group is left with $267.6 million under its authorization. Moreover, its dividend yield that outperforms the industry average makes it an attractive pick for yield-seeking investors.
XL GROUP Public Limited Company, an insurance and reinsurance company, provides property, casualty, and specialty products to industrial, commercial, and professional firms; and insurance companies and other enterprises worldwide. The company operates in two segments: Insurance and Reinsurance.
Diageo plc (ADR) (NYSE:DEO), ended its Monday’s trading session with -2.74% loss, and closed at $114.77.
Diageo plc (DEO) declared recently that it has purchased a 37 acre plot of land adjacent to its existing manufacturing facility in Plainfield, IL. The site, located at 14020 Coilplus Drive, presently houses a 246,000 square foot warehouse, which Diageo will put into immediate use to store finished case goods from its bottling operations across the street in addition to from other locations.
Diageo’s Plainfield, Illinois location is the primary manufacturing location for Diageo’s range of Smirnoff branded products and employs about 600 people.
Diageo has played a key role in the Illinois community for many years and seen a number of expansions and upgrades since its opening in 1966, counting a recently-accomplished $120 million enhancement. Diageo is proud that for two successive years it has been recognized as a Best Place to Work in Illinois.
Diageo plc manufactures and distributes premium drinks. Its products comprise Scotch and Irish whiskey, gin, vodka, rum, and ready to drink products, in addition to beer and spirits, Irish cream liqueur, Raki, wine, tequila, Canadian and American whiskey, adult beverages, Cachaça, and finishing centre products.
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.